People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DBV Technologies S.A. | — | Pharmaceuticals | Series D+ | $306.9M | $2.6B | 2025 |
Daniele Guyot-Caparros at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniele Guyot-Caparros on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Tasse | 1 | 4 |
| Mailys Ferrere | 1 | 2 |
| Pharis Mohideen | 1 | 2 |
| Julie O'Neill | 1 | 2 |
| Virginie Boucinha | 1 | 1 |
| Michel De Rosen | 1 | 1 |
| Timothy E. Morris | 1 | 1 |
| Michael Goller | 1 | 1 |
| Ravi Madduri Rao | 1 | 1 |
| Daniel Soland | 1 | 1 |
| Adora Ndu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.